Amyris Inks Deal For Third Clean Beauty Brand; Inter Parfums’ Third Quarter; Beauty News In Brief

Amyris will expand its platform of clean cosmetic brands beyond Biossance skin care and Pipette baby care with Rose Inc., a new line of cosmetic products planned under a deal with the same-named beauty commerce site. The parties will create a new company, Clean Beauty Collaborative, Inc., headed by Caroline Hadfield, president of Amyris’ clean skin-care ingredients business, while Rose Inc. founder Rosie Huntington-Whiteley will serve as Chief Creative Officer. Products from the new brand are expected to debut in the third quarter of 2021. John Melo, president and CEO of Amyris, which also provides sustainable ingredients to the personal-care and flavors and fragrances sectors, states, “We believe cosmetics to be the next opportunity for us to transform to clean.” Amyris, through Biossance, is an advocate of cosmetics regulatory reform in the US to better protect consumers. (Also see "Beautycounter-Led Coalition Lobbies For Tighter Cosmetics Regulations" - HBW Insight, 12 September, 2017.) Among other R&D priorities, the firm is working on developing “highly pure and efficacious CBD” through its proprietary technology platform, which uses engineered microorganisms to convert plant-sourced sugars into sustainable, custom molecules. (Also see "Amyris Making Headway In Fermentation-Derived Cannabinoids; CBD Could Hit Market In Early 2020 " - HBW Insight, 31 December, 2019.)

Inter Parfums, Inc. is optimistic about planned 2021 launches of its first products under licensing deals with Germany luxury fashion brand MCM and global life and style house Kate Spade New York, as well as highly anticipated GUESS Bella Vita and Anna Sui Sky, both postponed in 2020 due to COVID-19. “The 2021 new product pipeline is especially rich, and therefore we anticipate considerable sales gains over the current year,” says chairman and CEO Jean Madar in the prestige perfume and cosmetics firm’s 27 October announcement of fiscal 2020 third-quarter results. Net sales declined 16% to $160.6m for the period ended 30 September, with European sales down almost 10% to $130m, and US sales falling roughly 35% to $31m